BIRMEX and CIPLA sign an agreement for the supply of medicines in Mexico
Biological and Reagent Laboratories of Mexico (BIRMEX) said it signed a Strategic Association and Technology Transfer Agreement with the pharmaceutical company CIPLA from India.
The document contemplates the realization of commercial agreements to ensure the supply of oncological and retroviral drugs in our country in the short term, as well as a technology transfer scheme to ensure that BIRMEX can manufacture these products for the national supply.
CIPLA is the third largest pharmaceutical company in India, whose mission is to ensure access to high-quality medicines for the most vulnerable populations.
On behalf of the Indian company, the signing of the agreement in Mexico was attended by the senior director, head of International Business Development and Strategic Alliances, Deepak Mansukhani, and the global general counsel and executive vice president, A. S. Kumar.
The Mexican delegation was made up of authorities from the health sector, including General Jens Pedro Lohmann, general director of Birmex, an institution of the Mexican Government responsible for developing, producing, importing, and distributing vaccines and health supplies.
In April 2022, the Secretary of Foreign Affairs, Marcelo Ebrard Casaubon, made a trip to India to strengthen the Mexican health system by negotiating technology transfer agreements to produce vaccines and medicines in Mexico.
The major issues for the further development of the pharmaceutical market will be discussed at the Mexican Pharmaceutical Forum that will be organized by the Global Pharmaceutical Leaders’ Club on the 29-30th November 2022 in Mexico City. Secure your delegate place ASAP! Registration is here: https://mexicanpharmaforum.com/registration/
Takeda appoints Hernán Porcile as its new General Manager in Mexico
October 24, 2022
Solid growth of the Medical Devices sector in Mexico
October 19, 2022
Sandoz Receives Certification for Transparent Practices
October 19, 2022